A clinical trial comparing Armour Thyroid (NDT) and Levothyroxine (LT4) is now recruiting patients in the United States. The sponsor of the study is Allergan, the makers of Armour Thyroid in the United States. They hope to recruit 220 patients… Read More ›
Lack of knowledge about Free T3 peaks and valleys contributes to failure and frustration in T3-based therapies, including desiccated thyroid and T3-T4 combination therapy. On patient support groups, I often see conversations that go like this: “My FT3 result was… Read More ›
Sigh. Just sigh. Even some of our best thyroid patient advocates can unknowingly share misinformation about thyroid therapy. Mary Shomon’s thyroid articles on Verywell.com are usually to be trusted. But yesterday I was saddened to see that an article supposedly… Read More ›
If we want to disagree with the American Thyroid Association’s prejudice against animal sources of thyroid hormone, we should to at least prove we’re trying to listen to them. Then we should fairly point out what they didn’t say, what truths… Read More ›
Here I move on to part 2 of my summary of ATA thyroid therapy guidelines, where they try to defend the ethics their own stance (Jonklaas et al, 2014). Their self-righteous, defensive and arrogant reply to question 11 deserves its… Read More ›
Any fair criticism of a medication’s potential for harm or benefit should first examine the properties of the medication and how it interacts with the human body in general. Next, we should distinguish the content of a pharmaceutical tool from… Read More ›
By Tania S. Smith. Updated May 8, 2019 “Thyroid pharmaceutical prejudice” is simply a bias against one thyroid hormone pharmaceutical type in favor of another. Prejudice claims that a particular thyroid medication is intrinsically unsafe or ineffective, for all patients… Read More ›
This guest post is authored by Gisele Gautreau, a Canadian thyroid patient who has given us permission to share her image and story. Gisele: For those questioning the plight of thyroid patients in this country, the following is my story:… Read More ›